Core Viewpoint - The competition among domestic pharmaceutical companies in the field of myopia prevention drugs is intensifying, with Xingqi Eye Medicine leading the market by obtaining multiple approvals for atropine eye drops and advancing new drug trials [2][3][4]. Group 1: Product Approvals and Market Position - Xingqi Eye Medicine was the first in China to receive approval for 0.01% atropine eye drops in March 2024, establishing a competitive edge in the myopia prevention market [2][4]. - The company has also received approvals for 0.02% and 0.04% concentrations of atropine eye drops, enhancing its market position through a gradient concentration strategy [2][4]. - The newly approved SQ-24071 eye drops for clinical trials represent a significant milestone in the drug development process, indicating the transition from laboratory research to human testing [2][3]. Group 2: Financial Performance - Since the launch of its atropine eye drops, Xingqi Eye Medicine has experienced substantial revenue growth, with a 32.42% increase in revenue and a 40.84% increase in net profit for 2024 compared to 2023 [4]. - In the first three quarters of 2025, the company reported a 32.27% year-on-year increase in revenue and a remarkable 105.98% increase in net profit [5]. Group 3: Industry Trends and Future Outlook - The rising incidence of myopia in China, driven by excessive use of electronic devices and poor eye care habits, has created a significant public health issue, prompting increased competition among pharmaceutical companies [3]. - The approval of SQ-24071 eye drops signifies a shift in the myopia prevention market from single-product competition to a comprehensive strategy involving product matrices and service ecosystems [5].

Core Viewpoint - The company, Xingqi Eye Medicine, has received approval from the National Medical Products Administration for the clinical trial of its eye drop product SQ-24071, aimed at delaying myopia progression in children and adolescents [1]. Group 1 - The announcement was made on January 19, indicating the company's ongoing commitment to developing innovative treatments for eye health [1]. - SQ-24071 is classified as a modified new drug of chemical drugs category 2.2 and 2.4, highlighting its potential significance in the pharmaceutical market [1]. - The clinical trial approval marks a critical step in the product's development, which could address a growing concern regarding myopia in younger populations [1].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to delay the progression of myopia in children and adolescents [1] Group 1 - SQ-24071 eye drops are classified as a modified new drug of chemical drug category 2.2; 2.4 [1] - The company has completed various studies, including pharmaceutical and non-clinical pharmacology and toxicology, demonstrating good safety and clinical development value for SQ-24071 eye drops [1]

智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局签发的关于SQ-24071滴眼 液的《药物临床试验批准通知书》。SQ-24071滴眼液为公司研发的化学药品2.2;2.4类改良型新药。临床 拟用于延缓儿童及青少年的近视进展。根据改良型新药的有关要求,公司已经完成SQ-24071滴眼液药学 及非临床药理毒理学等多方面的研究，研究结果表明SQ-24071滴眼液具有良好的安全性及临床开发价 值。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to slow the progression of myopia in children and adolescents [1] Group 1 - SQ-24071 eye drops are classified as a modified new drug of chemical drugs category 2.2 and 2.4 [1] - The company has completed various studies on SQ-24071, including pharmaceutical and non-clinical pharmacology and toxicology, demonstrating good safety and clinical development value [1] - There are currently no similar eye drop formulations available in the domestic and international markets [1]

Core Viewpoint - The company, Xingqi Eye Medicine, has received approval from the National Medical Products Administration for clinical trials of SQ-24071 eye drops, aimed at delaying the progression of myopia in children and adolescents [1] Company Summary - Xingqi Eye Medicine announced on January 19 that it has obtained a clinical trial approval notice for SQ-24071 eye drops from the National Medical Products Administration [1]

Group 1 - The core point of the article is that Xingqi Eye Pharmaceutical (300573) has received approval from the National Medical Products Administration for the clinical trial of SQ-24071 eye drops, which are intended to slow the progression of myopia in children and adolescents [1] - SQ-24071 is classified as a chemical drug of category 2.2; 2.4, indicating it is a modified new drug [1] - The approval signifies a potential advancement in the treatment options available for myopia, a growing concern among younger populations [1]

证券代码：300573 证券简称：兴齐眼药 公告编号：2026-002 沈阳兴齐眼药股份有限公司 申请人：沈阳兴齐眼药股份有限公司 关于SQ-24071滴眼液获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，沈阳兴齐眼药股份有限公司（以下简称"公司"）收到国家药品监督 管理局签发的关于 SQ-24071 滴眼液的《药物临床试验批准通知书》。现将相关情 况公告如下： 一、药品基本情况 药品名称：SQ-24071 滴眼液 适应症：拟用于延缓儿童及青少年的近视进展。 通知书编号：2026LP00170、2026LP00171、2026LP00172、2026LP00173 剂型：滴眼液 申请事项：境内生产药品注册临床试验 注册分类：化学药品 2.2；2.4 类 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 14 日受理的 SQ-24071 滴眼液符合药品注册的有关要求，同意开展临床 试验。 二、药品研发及其他情况 SQ-24071 滴眼液为我公司研发的化学药品 2.2；2.4 类改良型新药。临 ...

资料显示，沈阳兴齐眼药股份有限公司位于辽宁省沈阳市沈河区青年大街125号企业广场B座30层，成 立日期1977年3月24日，上市日期2016年12月8日，公司主营业务涉及眼科药物研发、生产、销售。主营 业务收入构成为：滴眼剂82.15%，凝胶剂/眼膏剂16.70%，其他(补充)1.15%。 截至9月30日，兴齐眼药股东户数5.41万，较上期增加16.85%；人均流通股3480股，较上期减少 14.42%。2025年1月-9月，兴齐眼药实现营业收入19.04亿元，同比增长32.27%；归母净利润5.99亿元， 同比增长105.98%。 分红方面，兴齐眼药A股上市后累计派现11.66亿元。近三年，累计派现9.85亿元。 机构持仓方面，截止2025年9月30日，兴齐眼药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股712.64万股，相比上期增加362.84万股。南方中证500ETF（510500）位居第三大流通股 东，持股250.63万股，相比上期减少1.00万股。 1月16日，兴齐眼药涨1.89%，成交额8.99亿元。两融数据显示，当日兴齐眼药获融资买入额1.37亿元， 融资偿还1.10亿元，融资 ...

Group 1 - The company Xingqi Eye Medicine has received drug registration approval from the National Medical Products Administration for its 0.02% and 0.04% atropine sulfate eye drops on January 4, 2026 [2] - The company is currently coordinating its market promotion plan and is in the production preparation stage [2]